Table 3.
Upregulated gene sets in lipid metabolism in the LASCPC-01 cell line and SCNC patients.
| Gene Sets | LASCPC-01 | SCNC | ||||||
|---|---|---|---|---|---|---|---|---|
| Number | ES | p-value | FDR | Number | ES | p-value | FDR | |
| Glycerolipid Metabolism | 7 (39) | 0.34 | 0 | 0.30 | 5 (43) | 0.27 | 0.68 | 1.00 |
| Glycerophospholipid Metabolism | 20 (67) | 0.38 | 0 | 0.31 | 9 (70) | 0.25 | 0.73 | 1.00 |
| Glycosphingolipid Biosynthesis Lacto and Neolacto Series | 9 (24) | 0.53 | 0 | 0.19 | 11 (25) | 0.39 | 0.41 | 1.00 |
| Ether Lipid Metabolism | 7 (26) | 0.31 | 0.19 | 0.30 | 9 (29) | 0.37 | 0.39 | 1.00 |
Note: Number: number of genes contributing to the leading-edge subset within the gene set (number of genes in the gene set after filtering out these genes not in the expression dataset); ES: enrichment score; p-value: nominal p-value not adjusted for gene set size or multiple hypothesis testing; a p-value of zero (0) indicates an actual p-value of less than 0.001; and FDR: false discovery rate.